GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol

Key Findings:  CBD is an inverse agonist for GPR3, GPR6, and GPR12 and as such may play a therapeutic role for conditions such as Alzheimer's disease, Parkinson's disease, cancer, and infertility for example.

Type of Study:  Laboratory Study

Study Result:  Positive

Cannabinoids Studied:  Cannabidiol (CBD)

Phytocannabinoid Source:  Not Applicable

Chemotype:  Chemotype III

Form of Administration:  Not Applicable

Receptors Studied:  GPCR 3, GPCR 6

Study Location(s):  United States

Year of Pub:  2019

Link to study